Phenylalanine

Generic Name: Phenylalanine

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁NO_₂

CAS Number: 63-91-2

Unique Ingredient Identifier: 47E5O17Y3R

Background: Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.

Indication: L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.

Associated Therapies: Amino acid supplementation

Clinical Trials

Salivary Fluoride Clearance

Phase 1

Completed

Conditions: Caries

Interventions: Drug: 0 ppm F
Drug: 250 ppm F as MFP
Drug: 1100 ppm as MFP
Drug: 2800 ppm F as MFP

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Procter and Gamble

Target Recruit Count: 27

Registration Number: NCT06735235

Locations: 🇺🇸
Oral Health Science Center, Mason, Ohio, United States

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

Phase 2

Not yet recruiting

Conditions: Malignant Brain Neoplasm

Interventions: Procedure: Computed Tomography
Drug: Fluorodopa F 18
Procedure: Positron Emission Tomography

First Posted Date: 2024-10-31

Last Posted Date: 2025-03-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 47

Registration Number: NCT06667726

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Unresectable HER2-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma

Interventions: Drug: Abemaciclib
Drug: Anastrozole
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Diagnostic Imaging
Drug: Exemestane
Other: Fludeoxyglucose F-18
Drug: Fluorine F 18 Fluoro Furanyl Norprogesterone
Drug: Fulvestrant
Biological: Gonadotropin-releasing Hormone Analog
Drug: Letrozole
Procedure: Positron Emission Tomography
Drug: Tamoxifen
Drug: Therapeutic Estradiol

First Posted Date: 2023-12-21

Last Posted Date: 2025-03-12

Lead Sponsor: University of Washington

Target Recruit Count: 60

Registration Number: NCT06179303

Locations: 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Short Course Radiotherapy for the Treatment of Patients with Glioblastoma, SAGA Study

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Radiation: Accelerated Hypofractionated Radiation Therapy
Procedure: Computed Tomography
Drug: Fluorodopa F 18
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Temozolomide
Procedure: Biospecimen Collection

First Posted Date: 2023-03-23

Last Posted Date: 2025-03-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 170

Registration Number: NCT05781321

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States

and more 5 locations

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: IBI334 E
Drug: IBI334 D
Drug: IBI334 C
Drug: IBI334 B
Drug: IBI334 A
Drug: IBI334 F

First Posted Date: 2023-03-20

Last Posted Date: 2023-11-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 128

Registration Number: NCT05774873

Locations: 🇦🇺
Westmead Hospital, Waratah, New South Wales, Australia

A HR20031 BE Study on Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: ARM F
Drug: ARM D
Drug: ARM A
Drug: ARM B
Drug: ARM E
Drug: ARM C

First Posted Date: 2023-01-12

Last Posted Date: 2023-04-07

Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT05682495

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Active, not recruiting

Conditions: Resectable Soft Tissue Sarcoma
Soft Tissue Sarcoma
Recurrent Soft Tissue Sarcoma

Interventions: Drug: Fluorodopa F 18
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Procedure: Surgical Procedure

First Posted Date: 2022-09-29

Last Posted Date: 2024-07-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 9

Registration Number: NCT05560009

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Depression and Driving

Recruiting

Conditions: Depression
Drive

Interventions: Drug: F 18 AV-1451 (Flortaucipir)
Drug: [11C]-Pittsburgh Compound B ([11C]PiB)

First Posted Date: 2022-07-07

Last Posted Date: 2023-07-27

Lead Sponsor: Ganesh Babulal

Target Recruit Count: 150

Registration Number: NCT05446805

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

Phase 1

Completed

Conditions: Healthy Volunteers; High Cholesterol

Interventions: Drug: NNC0385-0434 G
Drug: NNC0385-0434 F
Drug: NNC0385-0434 B

First Posted Date: 2022-04-18

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 152

Registration Number: NCT05333107

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc., Los Angeles, California, United States
🇺🇸
Altasciences, Cypress, California, United States

Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: Treatment A
Drug: Treatment F
Drug: Treatment B
Drug: Treatment C
Drug: Treatment G
Drug: Treatment D
Drug: Treatment H
Drug: Treatment E

First Posted Date: 2021-03-15

Last Posted Date: 2021-09-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT04798222

Locations: 🇩🇪
Research Site, Berlin, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy